Segments - Schedule of Segment Reporting Expenses (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Segment loss	$ 28,269			$ 62,014			$ 132,796	$ 175,045
Reconciliation of segment loss
Interest and other (income) expense, net	(2,783)			(5,128)			(9,452)	(16,663)
Interest expense	815			877			2,423	2,190
Net loss	26,301	$ 43,300	$ 56,166	57,763	$ 55,854	$ 46,955	125,767	160,572
Reportable Segment
Operating expenses:
Bexotegrast - clinical trial and third party contracting costs	4,526			26,713			39,474	70,290
Employee-related expenses - research and development (excluding stock-based compensation)	5,180			8,778			26,010	26,297
General and administrative costs (excluding stock-based compensation)	6,261			8,963			25,497	26,089
Other segment items	12,302			17,560			41,815	52,369
Segment loss	28,269			62,014			132,796	175,045
Reconciliation of segment loss
Interest and other (income) expense, net	(2,783)			(5,128)			(9,452)	(16,663)
Interest expense	815			877			2,423	2,190
Net loss	$ 26,301			$ 57,763			$ 125,767	$ 160,572